Joseph la Conti
Rheumatology · Miami, FLNPI 1831465954
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $279,288 of the $345,424 with a category attached, or 80.9%. AbbVie accounts for 70.0% of it on its own, with 40 other manufacturers making up the rest. 2025 is the largest year on record at $112,877, 9.0 times the $12,495 reported in 2019. Among rheumatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,198 payments — averaging $288.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$242K
- GSK$85K
- Johnson & Johnson$6K
- Amgen$2K
- Mallinckrodt Hospital Products Inc.$2K
- UCB, Inc.$1K
- plus $7K from 35 others
Across 10 payments — averaging $31,581 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$291K
- Eli Lilly$19K
- UCB SA$6K
What the payments were for
- Consulting fees$8,4452%
- Speaking & faculty fees$279,28881%
- Grants$2400%
- Travel & lodging$32,7839%
- Food & beverage$24,6487%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$345,424 in reported general payments places this provider in the 95th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 12 | $457,777 |
| Humira(Cf) PenAdalimumab | 57 | $433,357 |
| RinvoqUpadacitinib | 31 | $255,715 |
| BenlystaBelimumab | 46 | $234,324 |
| OfevNintedanib Esylate | 14 | $185,586 |
| XeljanzTofacitinib Citrate | 22 | $135,775 |
| EnbrelEtanercept | 15 | $130,800 |
| Actemra ActpenTocilizumab | 24 | $128,310 |
| OtezlaApremilast | 19 | $100,929 |
| ProliaDenosumab | 61 | $98,627 |
| Orencia ClickjectAbatacept | 11 | $61,642 |
| OlumiantBaricitinib | 15 | $41,652 |
| RasuvoMethotrexate/Pf | 27 | $19,663 |
| Hydroxychloroquine Sulfate | 401 | $14,289 |
| LovazaOmega-3 Acid Ethyl Esters | 11 | $12,702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa, Enbrel, Otezla, Prolia | $2,423 | $788,133107 claims |
| AbbVieRinvoq | $241,935 | $255,71531 claims |
| GSKBenlysta | $84,694 | $234,32446 claims |
| Boehringer IngelheimOfev | $861 | $185,58614 claims |
| PfizerXeljanz | $288 | $135,77522 claims |
| Lilly USA, LLCOlumiant | $456 | $41,65215 claims |
| Medexus Pharma, Inc.Rasuvo | $13 | $19,66327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Miami
- Michael WeitzMiami$658K
- Robert HoffmanMiami$241K
- Christopher MesaMiami$198K
- George MunozMiami$147K
- Santiago de SoloMiami$98K
- Carlos LozadaMiami$97K
- Reuven BrombergMiami$78K
- Jeffrey RitterMiami$39K
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.